A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2006; you can also visit the original URL.
The file type is
In Vivo Selection for Human and Murine Hematopoietic Cells Transduced with a Therapeutic MGMT Lentiviral Vector that Inhibits HIV Replication
We have developed an HIV-based lentiviral vector, VRX496, which efficiently transduces human CD34 + progenitors and CD4 + T lymphocytes. VRX496 contains an antisense sequence against the HIV envelope and is currently being evaluated for safety in a clinical trial for treatment of HIV. Selective outgrowth of transduced hematopoietic cells in vivo is anticipated to increase the therapeutic efficacy of this treatment by maximizing the persistence of virus-resistant cells in the body. Although HIVdoi:10.1016/j.ymthe.2003.11.003 pmid:14759800 fatcat:ne7ese4h2ffojdymnc7wksefqa